Navigation Links
FDA approves Incivek for hepatitis C
Date:5/23/2011

SILVER SPRING, Md., May 23, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The current standard of care for patients with chronic hepatitis C infection is peginterferon alfa and ribavirin taken for 48 weeks. Less than 50 percent of patients respond to this therapy.

The safety and effectiveness of Incivek was evaluated in three phase 3 clinical trials with about 2,250 adult patients who were previously untreated, or who had received prior therapy. In all studies patients also received the drug with standard of care. In previously untreated patients, 79 percent of those receiving Incivek experienced a sustained virologic response (i.e. the infection was no longer detected in the blood 24 weeks after stopping treatment) compared to standard treatment alone.

The sustained virologic response for patients treated with Incivek across all studies, and across all patient groups, was between 20 and 45 percent higher than current standard of care.

The studies indicate that treatment with Incivek can be shortened from 48 weeks to 24 weeks in most patients. Sixty percent of previously untreated patients achieved an early response and received only 24 weeks of treatment (compared to the standard of care of 48 weeks). The sustained virologic response for these patients was 90 percent.

When a person achieves a sustained virologic response after completing treatment, this suggests that the hepatitis C infection has been cured.

Sustain
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Sutent for Rare Type of Pancreatic Cancer
2. FDA Approves New HIV Treatment
3. FDA Approves Victrelis for Hepatitis C
4. FDA Approves New Treatment for Rare Type of Pancreatic Cancer
5. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
6. FDA Approves Tradjenta™ (linagliptin) Tablets for the Treatment of Type 2 Diabetes
7. FDA Approves New Treatment for Type 2 Diabetes
8. FDA Approves Zytiga for Late-Stage Prostate Cancer
9. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
10. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
11. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Breckenridge Pharmaceutical, Inc. announced today that it ... Pvt. Ltd. ( Hyderabad, India ) under ... ANDAs.  Under the terms of the agreement, MSN will ... for the U.S. market, and Breckenridge will market and ... have agreed to develop an oral antibiotic with current ...
(Date:12/19/2014)... 19, 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch ... pleased to provide this review of the Company,s recent ... "Over this past year, we achieved many ... extremely proud to say that Monarch America is in ... has ever been," stated Eric Hagen , CEO ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... ... - Spreads Messages of Hope to Others with Diabetes and Steers Toward Its ... of Tour de France Competition, BRIDGEWATER, N.J., April 2, 2008 ,Sanofi-aventis announced today ... of,Team Type 1, a team of amateur and professional cyclists living with type 1,diabetes., ...
... Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MTA) today ... for review CTI,s Marketing Authorization,Application (MAA) for XYOTAX(TM) ... non-small cell lung cancer (NSCLC),with ECOG (Eastern Cooperative ... MAA at the beginning of March. The validation ...
Cached Medicine Technology:Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 2Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 3Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 4Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 5European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 2European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 3European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 4
(Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... Austin, Texas (PRWEB) December 22, 2014 ... hustle and bustle of Black Friday shopping and opted ... publishing and marketing education company, for their 5th annual ... Marketer charged just $7 to attend the 5 ... sales that they promptly donated to support two Central ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/21/2014)... In this report, the global powered ... product, and application. The market, by power source, ... By product, the market covers the handpieces; power ... market is further subdivided into drills, saws, reamers, ... shavers, wire/pin drivers, and others. Moreover, the power ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... May 6 Volcano Corporation (Nasdaq: VOLC ... of products for the diagnosis and treatment of coronary ... be participating in the Bank of America and Merrill ... presentation by Scott Huennekens, president and chief executive officer, ...
... Incorporated has initiated a voluntary, nationwide recall of one lot ... healthcare professionals as an aid in the diagnosis of myocardial ... to reports of low recovery of quality control samples containing ... affected lot. Although there have been no reported issues ...
... HOUSTON - A newly discovered gene known as DEAR1 is ... local recurrence-free survival in early-onset breast cancer, a research team ... Anderson Cancer Center reports in the journal PLoS Medicine ... because so many young women have recurrences in the breast, ...
... The Mobile Massage Team ( www.mobilemassageteam.com ), a ... programs, promotional events, and special affairs, today announced that the ... Annual GlobalFit Worksite Wellness Summit ( http://www.globalfit.com/summit/ ... Down Town Club in Center City Philadelphia. Team members ...
... - Leadership in Fight Against Tobacco Recognized Nationally -WASHINGTON, May ... of Greenfield, Ind., has been named the National Youth Advocate ... her leadership in the fight against tobacco. Emily is being ... 6) with four regional winners and a group winner. (Logo: ...
... released today by Ernst Berndt and Mark Trusheim of ... that eliminating FDA,s preemption protection would decrease patients, access ... reduce medical device industry employment. The paper, ... Devices on Patients, Innovation and Jobs," comes as ...
Cached Medicine News:Health News:Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast 2Health News:Biosite Incorporated Issues Voluntary, Nationwide Recall for Cardiac Marker Test 2Health News:Novel gene predicts local recurrence in early onset breast cancer 2Health News:Novel gene predicts local recurrence in early onset breast cancer 3Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Removing Medical Device Preemption Impacts Jobs, Health Care Costs, Patient Access 2
... TOPS is a support catheter which assists ... angioplasty or stenting. The spiral catheter offers ... with .014 to .018 steerable guidewires to ... occlusion is crossed, TOPS is withdrawn while ...
... are indicated for the removal ... thrombi from vessels in the ... also be used for temporary ... of fluids, and blood sampling. ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
Medicine Products: